Pfizer CEO touts $80 billion in deals, but says 'the real test' is still ahead
Pfizer CEO touts $80 billion in deals, but says 'the real test' is still ahead
Pfizer CEO touts $80 billion in deals, but says 'the real test' is still ahead
Key points
اہم نکات
मुख्य बातें
- Pfizer's chief executive has pointed to $80 billion worth of deals as a sign of the drugmaker's direction, while cautioning that the real test still lies ahead.
- Investors will now be watching whether those deals turn into lasting growth for the company, rather than judging them on their headline value alone.
- Pfizer's chief executive has pointed to $80 billion worth of deals as a sign of the drugmaker's direction, while cautioning that the real test still lies ahead.
- Investors will now be watching whether those deals turn into lasting growth for the company, rather than judging them on their headline value alone.
- Pfizer's chief executive has pointed to $80 billion worth of deals as a sign of the drugmaker's direction, while cautioning that the real test still lies ahead.
- Investors will now be watching whether those deals turn into lasting growth for the company, rather than judging them on their headline value alone.
Pfizer's chief executive has pointed to $80 billion worth of deals as a sign of the drugmaker's direction, while cautioning that the real test still lies ahead. Investors will now be watching whether those deals turn into lasting growth for the company, rather than judging them on their headline value alone.
Pfizer's chief executive has pointed to $80 billion worth of deals as a sign of the drugmaker's direction, while cautioning that the real test still lies ahead. Investors will now be watching whether those deals turn into lasting growth for the company, rather than judging them on their headline value alone.
Pfizer's chief executive has pointed to $80 billion worth of deals as a sign of the drugmaker's direction, while cautioning that the real test still lies ahead. Investors will now be watching whether those deals turn into lasting growth for the company, rather than judging them on their headline value alone.
Most read
سب سے زیادہ پڑھی گئی
सबसे ज़्यादा पढ़ी गई
- Loading...
Get news in your inbox
خبریں اپنے ان باکس میں حاصل کریں
खबरें अपने इनबॉक्स में पाएं
One email when new stories are published. No spam, unsubscribe anytime.
نئی خبریں شائع ہونے پر ایک ای میل۔ کوئی سپیم نہیں، کسی بھی وقت ان سبسکرائب کریں۔
नई खबरें प्रकाशित होने पर एक ईमेल। कोई स्पैम नहीं, कभी भी अनसब्सक्राइब करें।